Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Thoracic Cancer ( IF 2.3 ) Pub Date : 2020-05-29 , DOI: 10.1111/1759-7714.13488
Minjiang Chen ₁ , Qiang Li ₂ , Yan Xu ₁ , Jing Zhao ₁ , Li Zhang ₁ , Lijuan Wei ₂ , Wei Zhong ₁ , Mengzhao Wang ₁

Affiliation

Real‐world evidence of second‐line treatment and beyond with immune checkpoint inhibitors (ICIs) in Chinese patients is lacking. Here, we aimed to assess the efficacy, responses, and immune‐related side effects of anti‐PD‐1 agents in real‐life practice.

更新日期：2020-05-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11